Publications

IN 2019, ST. CATHERINE HOSPITAL PLAYED A CRUCIAL ROLE IN THE IMPLEMENTATION OF PERSONALIZED MEDICINE IN CLINICAL PRACTICE

During 2019, physicians from St. Catherine Hospital published ten scientific articles in journals indexed in Science Citation Index and Current Contents, two scientific articles published in journals indexed in other indexing services, a book chapter published by Springer, and 11 scientific abstracts, all from the field of personalized medicine. At the same time, in 2019, physicians from St. Catherine hospital gave 40 invited lectures in different areas of personalized medicine.

Selected publications in 2019:

Borić I, Hudetz D, Rod E, Jeleč Ž, Vrdoljak T, Skelin A, Polašek O, Plečko M, Trbojević-Akmačić, Lauc G, Primorac D. “A 24-Month Follow-Up Study of the Effect of Intra-Articular Injection of Autologous Microfragmented Fat Tissue on Proteoglycan Synthesis in Patients with Knee Osteoarthritis”. Genes (Basel). 2019;10(12):1051-60.; https://doi.org/10.3390/genes10121051

The purpose of this study was to evaluate the effect of micro-fragmented fat tissue intra-articular injection 24 months after application in two ways: Indirectly using functional magnetic resonance imaging (MRI) assessment analyzing the glycosaminoglycans (GAG) content in cartilage by means of delayed gadolinium (Gd)-enhanced magnetic resonance imaging of cartilage (dGEMRIC), as well as clinical outcome on observed level of GAG using standard orthopedic physical examination including VAS assessment. 10 patients (18 knees)  were included in a 24-month follow-up. Surgical intervention (lipoaspiration), followed by tissue processing and intra-articular injection of the final microfragmented adipose tissue product into the affected knee(s), was performed in all patients. Patients were assessed for a visual analog scale (VAS), dGEMRIC at the baseline, three, six, 12 and 24 months after the treatment. A magnetic resonance sequence in dGEMRIC due to infiltration of the anionic, negatively-charged contrast gadopentetate dimeglumine (Gd-DTPA2) into the cartilage indicated that the contents of cartilage glycosaminoglycans significantly increased in specific areas of the treated knee joint. Our results suggest that this method of single intra-articular injection of autologous microfragmented adipose tissue improves GAG content on a significant scale, with over half of the measurements suggesting relevant improvement 24 months after intra-articular injection opposed to the expected GAG decrease over the natural course of the disease

Polančec D, Zenić L, Hudetz D, Borić I, Jeleč Z, Rod E, Vrdoljak T, Skelin A, Plečko M, Turkalj M, Nogalo B, Primorac D. Immunophenotyping of a Stromal Vascular Fraction from Microfragmented Lipoaspirate Used in Osteoarthritis Cartilage Treatment and Its Lipoaspirate Counterpart. Genes (Basel). 2019;10(6):474-85. doi: 10.3390/genes10060474.

The aim of the study was to characterize a stromal vascular fraction from microfragmented lipoaspirate (SVF-MLA) applied for cartilage treatment in OA and compare it to that of autologous lipoaspirate (SVF-LA). In SVF-LA and SVF-MLA samples, the following population phenotypes were identified within the CD45 fraction: endothelial progenitors (EP), mature endothelial cells, pericytes, transitional pericytes, and supra-adventitial-adipose stromal cells (SA-ASC). The immunophenotyping profile of SVF-MLA was dominated by a reduction of leukocytes and SA-ASC, and an increase in EP, evidencing a marked enrichment of this cell population in the course of adipose tissue microfragmentation. The role of EP in pericyte-primed MSC-mediated tissue healing, as well as the observed hormonal implication, is yet to be investigated

Hudetz D, Borić I, Rod E, Jeleč E, Kunovac B, Polašek O, Vrdoljak T, Plečko M, Skelin A, Polančec D, Zenić L, Primorac D. Early results of intra-articular micro-fragmented lipoaspirate treatment in patients with late stages knee osteoarthritis: a prospective study. CMJ. 2019;60(3):227-36.

The aim of this study was to analyze clinical and functional effects of intra-articular injection of autologous micro-fragmented lipoaspirate (MLA) in patients with late stage knee osteoarthritis (KOA). Secondary aims included classifying cell types con- tributing to the treatment effect, performing detailed MRI- based classification of KOA, and elucidating the predictors for functional outcomes. Seventeen patients (85%) showed a substantial pattern of KOOS and WOMAC improvement, significant in all accounts. KOOS score improved from 46 to 176% when compared with baseline, WOMAC decreased from 40 to 45%, while VAS rating decreased from 54% to 82% (all P values were <0.001). Three patients (15%) received a total knee replace- ment and were not followed up completely.

Hudetz D, Jeleč Ž, Rod E, Borić I, Plečko M, Primorac D. The Future of Cartilage Repair. In: Personalized Medicine in Healthcare Systems: legal, Medical and Economic Implications. (Editors: Nada Bodiroga-Vukobrat, Daniel Rukavina, Krešimir Pavelić, Gerald G. Sander). Cham: Springer Nature Switzerland, Switzerland; 2019. p.375-411.

Articular cartilage is a hyaline cartilage 2-4 mm thick. It is composed of a 95% of dense extracellular matrix (ECM) and 5% of highly specialized cells called chondrocytes. Due to its avascular, aneural and alymphatic state, it has a limited repair potential. Articular cartilages’ main function is to provide smooth, lubricated surface for low friction articulation and at the same time articular cartilage minimizes the stress and strains on the matrix. Articular cartilage could be damaged by normal wear and tear or injury and it can cause severe pain, inflammation and some degree of disability.  Its management consist of pharmacological (acetaminophen, NSAID, salicylate, selective COX-2 inhibitors or opioids) and non-pharmacological therapies. Non-pharmacological treatment includes physical therapy and decreasing the load in the joint by modifying patient’s habits. A new class of agents (symptomatic or disease modifying osteoarthritic drugs (S/DMOADs) including glucosamine and chondroitin sulfate is receiving wide publicity. At the same time, numerous published reports advising the use of hyaluronic acid injections: viscosupplementation in patients with symptomatic osteoarthritis. Operative treatment includes different surgical debridement and microfracture techniques, osteochondral autograft transfers, osteochondral allograft transplantation, etc. New techniques and concepts are being developed not only to treat damaged or diseased joint cartilage but also to find ways of achieving regeneration to normal cartilage that will give long-lasting improvements and allow patients to return to a fully active lifestyle. Nevertheless, as two stage procedures involving cell culture are expensive and cumbersome, there is an increasing push towards a single stage stem cell treatment. Currently, there are a number of new methods with cartilage repair aim, including autologous chondrocyte implantation (ACI), matrix-induced autologous chondrocyte implantation (MACI), intra-articular administration of autologous microfragmented fat tissue with Ad-MSCs, etc. In this chapter, we will discuss some current treatments and the emerging strategies/techniques employed by researchers and physicians thriving to repair articular cartilage through biological means.

Mandac Rogulj I, Matišić V, Arsov B, Boban L, Juginović A, Molnar V, Primorac D. Dasatinib-induced nephrotic syndrome: a case of phenoconversion. CMJ. 2019;60(3):250-54.

We present the case of a 33-year-old chronic myeloid leu-kemia (CML) female patient, in whom the occurrence of nephrotic syndrome, during the treatment with tyrosine kinase activity inhibitors (TKIs), was potentially influenced by transient phenoconversion. Seven years after the CML diagnosis in 2004 and complete response, the patient experienced pain in the mandible and extremities. After this, imatinib was replaced by nilotinib, but generalized maculopapular rash was presented and successfully treated with antihistamines. The therapy was then discontinued due to planned pregnancy, and the patient experienced a relapse of CML with BCR-ABL/ABL1 transcripts of 18.9%. Dasatinib was introduced, and CML was in remission. Two years later, urine protein levels (6.19 g/L) and erythrocyte sedimentation rate were elevated (ESR = 90 mm/3.6 ks). The patient was diagnosed with nephrotic syndrome. With dasatinib dose reduction, urine protein level returned to the reference range. In order to determine the best genotype-guided therapy, the patient underwent pharmacogenomic testing, showing a homozygous CYP3A4 genotype *1/*1, associated with extensive metabolizer (EM) enzyme phe- notype, typical for normal rates of drug metabolism for TKIs. However, this was inconsistent with nephrotic syndrome occurrence. A possible explanation would be CYP3A4 EM genotype coding a poor metabolizer enzyme phenotype, leading to the drug accumulation in the patient’s blood. This transient phenoconversion can be explained by inflammation with elevated ESR during nephrotic syndrome. This case shows that a broader approach that recognizes genetic, clinical, and epigenomic factors is required for a quality decision on the personalized therapy regimen.

Turkalj M, Matišić V, Šimić A, Juginović A, Erceg D, Tješić Drinković D, Höppner W, Primorac D. Cystic fibrosis presentation in del. F508 and p. Tyr109Glyfs compound heterozygote CFTR state: a case report. CMJ. 2019;60(3):246-9.

We report a case of cystic fibrosis (CF) in a 15-year-old female patient who is a compound heterozygote for CFTR gene, with delta F508 and Tyr109Glyfs mutations detected. This is the first detailed description of such a case in the medical literature. The primary CF presentation occurred at the age of 9 in the form of gastrointestinal symptoms including greasy, bulky, and foul-smelling stool. The patient exhibited delayed growth, with her height and weight being below the 5th centile for age according to the World Health Organization growth curves. Pancreatic enzyme supplement treatment was started immediately, alongside high-fat and high-calorie diet, resulting in patient’s recovery and development. DNA analysis of CFTR gene demonstrated the presence of del. F508 mutation and a rare combining deletion and insertion mutation p. Tyr109Glyfs. The combination of the two mutations is very rare in CF patients and is therefore valuable to document this case in order to provide information on disease progression, therapy options, and outcomes. With standard treatment and early diagnosis, the patient is currently doing well and is not restricted by the disease in her daily and sports activities.

Jeleč Ž, Primorac D, Antičević D. Personalized surgery approach in severe form of osteogenesis imperfecta type III: point of view. J Pediatr Orthop B. 2019;28(5):505-8.

Osteogenesis imperfecta (OI) is a genetic disorder characterized by fragile bones. It is our aim to illustrate variability in clinical presentation of severe form of OI. As an example of personalized surgery approach we present an 11-year-old girl with OI type III. Prior to referral to our hospital, she was treated with 18 cycles of bisphosphonates as well as with several different surgical procedures. Due to no improvement in her mobility status she underwent two additional surgeries at our hospital with a 5-month interval between them. Prior to the surgery, molecular genetic analysis was performed and the clinical diagnosis of OI was confirmed. Using the Fassier-Duval intramedullary telescoping nail, we performed correction osteotomies of both femurs and lower legs in two separate settings, with a very good final result. According to our experience, the Fassier-Duval nailing system is good option, but one should pay attention to many details while performing surgery. Thus, making treatment of OI patients very personalized. In this paper we present a unique personalized approach in OI: firstly, diagnosing COL1A1 gene mutations and secondly, performing a complex two-part surgery.

Pavlović T, Štefančić K, Rožanković M, Boban L, Borić I, Molnar V, Zekan P, Primorac D. Radiol Case Rep. 2019;15(2):136-40. doi: 10.1016/j.radcr.2019.10.031.

We report a case of a 39-year old male patient who presented to us with several months of lower back pain. Following clinical assessment, the patient underwent a magnetic resonance imaging exam, which after using advanced imaging protocols showed a ventrolateral disc hernation toward the psoas muscle. Based upon the findings in the magnetic resonance and the electromyoneurographic examination, the decision was made to treat the patient conservatively. Coronal planes are useful for discerning changes of various origins not usually seen on the sagital and axial planes. If needed, additional advanced protocol is available for increased specificity and diagnostic accuracy.

Bach-Rojecky L, Vađunec D, Lozić M, Žunić K, Špoljar GG, Čutura T, Erceg D, Primorac D. Challenges in anesthesia personalization: resolving the pharmacogenomic puzzle. Per Med. 2019;16(6):511-25. doi: 10.2217/pme-2019-0056.

Clinicians are witnessing differences in the doses required for induction and maintenance of anesthesia, as well as prolonged recovery in some patients. Predictable factors like patient characteristics, factors related to the procedure, pharmacological characteristics of anesthetics and adjunctive drugs, might explain some of the observed differences. However, the role of various polymorphisms of genes encoding for drugs' molecular targets, transporters and metabolic enzymes can have a significant impact on anesthesia outcome, too. In the present paper, we critically discuss pharmacological characteristics of the most common drugs used in anesthesia, with a focus on the possible genetic background of unpredictable diversities in anesthesia outcomes.

Rod E, Matić I, Antunović M, Vetma V, Pavičić I, Hudetz D, Marijanović I, Primorac D, Ivković A. Optimization of an ex vivo gene transfer to the hamstrings tendons muscle remnants: potential for genetic enhancement of bone healing. Croat Med J. 2019;60(3):201-11.

Aim of this study was to assess whether an adenoviral vector carrying the bone morphogenetic protein genes (Ad.BMP-2) can transduce human muscle tissue and direct it toward osteogenic differentiation within one hour. This in vitro study, performed at the Department of Molecular Biology, Faculty of Science, Zagreb from 2012 to 2017, used human muscle tissue samples collected during anterior cruciate ligament reconstructions performed in St Catherine Hospital, Zabok. Samples from 28 patients were transduced with adenoviral vector carrying firefly luciferase cDNA (Ad.luc) by using different doses and times of transduction, and with addition of positive ions for transduction enhancement. The optimized protocol was further tested on muscle samples from three new patients, which were transduced with Ad.BMP-2. Released bone morphogenetic protein 2 (BMP-2) levels in osteogenic medium were measured every three days during a period of 21 days. Expression of osteogenic markers was measured at day 14 and 21. After 21 days of cultivation, muscle tissue was immunohistochemically stained for collagen type I detection (COL-I). The new transduction protocol was established using 108 plaque-forming units (P<0.001) as an optimal dose of adenoviral vector and 30 minutes (P<0.001) as an optimal contact time. Positive ions did not enhance transduction. Samples transduced with Ad.BMP-2 according to the optimized protocol showed enhanced expression of osteogenic markers (P<0.050), BMP-2 (P<0.001), and COL I. This study confirms that Ad.BMP-2 can transduce human muscle tissue and direct it toward osteogenic differentiation within 30 minutes.

Bach-Rojecky L, Vađunec D, Žunić K, Kurija J, Šipicki S, Gregg R, Mikula I, Primorac D. Continuing war on pain: a personalized approach to the therapy with nonsteroidal anti-inflammatory drugs and opioids. Per Med. 2019;16(2):171-84.

Successful pain management requires the delivery of analgesia with minimal risk of adverse drug reactions. Nonsteroidal anti-inflammatory drugs and opioids remain the mainstay of treatment for the majority of patients. Unfortunately, almost 50% of all patients experience inadequate pain relief and serious side effects. Allelic variants in genes coding for target proteins, transporters and enzymes, which govern analgesic drugs action and their fate in the organism, might explain inter-individual variability in pain severity and in drug-induced pain relief and toxicities. Additionally, it seems that epigenetic changes contribute to the highly variable response to pain treatment. Therefore, pharmacogenomic testing might be a valuable tool for personalization of pain treatment, with a multidisciplinary team approach involved.

Primorac D and Bach-Rojecky L. Could a Personalized Approach to Therapy End the war on Pain?

Practical Pain Management. 2019;19(3):50-3.

Chronic pain affects around 20% of the adult population worldwide and represents a huge burden for the affected individuals, with a significant negative impact on their quality of life, daily functioning, and work productivity. Consequently, the financial direct and indirect cost of chronic pain on an annual basis is enormous, ranging from $560 to 635 billion. Chronic pain denotes one of the greatest challenges in contemporary medicine, both from the aspect of basic researchers seeking an explanation of complex pain mechanisms, to clinicians trying to find an optimal therapeutic strategy for their patients. Although findings from laboratories often contribute to the clarification of complex pain pathophysiology and suggest novel molecular targets, pain treatment is still grounded on two classes of analgesic drugs: NSAIDs and opioids. Responses to these “pain killers” vary to a great degree (~40-fold), with nearly 50% of all patients experiencing inadequate pain relief as well as various disturbing or even unbearable side effects. Considering challenges in individual pain treatment, pharmacogenomic studies may clarify inter-individual differences in analgesic efficacy and tolerability. At St. Catherine’s Hospital, in Croatia, in collaboration with OneOme, co-founded by the Mayo Clinic, clinicians are routinely using PGx tests (Right-Med) “covering” CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, OPRM1, and COMT genes in order to design a successful pain management protocol. The risk of adverse drug reactions are minimized while patient outcomes are optimized. Due to multiple factors involved in this type of decision-making, which integrates not only knowledge of pharmacogenetics and epigenetics, but also of individual medication’s pharmacological characteristics and their interactions with other drugs and xenobiotics, a multidisciplinary team approach is necessary. This practice works to enable optimal, timely, evidence-based, and cost-effective pain management. Going forward, the authors strongly believe that to meet current challenges in individual pain treatment, clinicians should place crucial importance on additional pharmacogenomics to help clarify inter-individual differences in analgesic effect and tolerability of the drugs before engaging in a full treatment plan.

Ašić A, Salazar R, Storm N, Doğan S, Höppner W, Marjanović D, Primorac D. Population study of thrombophilic markers and pharmacogenetic markers of warfarin prevalence in Bosnia and Herzegovina. Croat Med J. 2019;60(3):212-20.

The aim of this study was to investigate the prevalence of common genetic variants that can serve as markers of thrombophilia and warfarin pharmacogenetics in Bosnia and Herzegovina. The study was performed between August and October 2017, on 130 healthy unrelated adult volunteers from Bosnian-Herzegovinian population sample. The prevalence of the following genetic variants was determined: F5 c.1601G>A (factor V Leiden), F2 c.*97G>A (factor II or prothrombin mutation), F13A1 (factor XIII) c.103G>T, MTHFR (methylenetetrahydrofolate reductase) c.665C>T and c.1286A>C, as well as PAI-1 (plasminogen activator inhibitor 1) c.-816A>G and c.-844G>A as markers of thrombophilia risk, and *2 and *3 alleles of CYP2C9 (cytochrome P450 2C9) and five variants of VKORC1 (vitamin K epoxide reductase complex subunit 1) as markers of warfarin pharmacogenetics. DNA was isolated from buccal swabs using salting out method, while genotyping was performed using matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry. Minor allele frequencies for two main thrombophilia risk factors, F5 c.1601G>A and F2 c.*97G>A were 0.023 and 0.008, respectively. Combined data for the markers of warfarin pharmacogenetics imply that 57.4% study participants can be expected to metabolize warfarin at an extensive, 40.3% at intermediate, and 2.3% at a poor rate. This study reports the first extensive population genetic data for thrombophilia and warfarin pharmacogenetic markers in Bosnia and Herzegovina. Allele frequencies of genetic variants are within the general average for European populations, and their presence implies the necessity of introduction of personalized medicine in warfarin-mediated antithrombotic therapy.


Articles published in journals listed in Science Citation Index and Current Contents.

       2020.

  1. Primorac D, Bach-Rojecky L, Vađunec D, Juginović A, Žunić K, Matišić V, Skelin A, Arsov B, Boban L, Erceg D, Erceg Ivkošić I, Molnar V, Ćatić J, Mikula I, Boban Lj, Primorac L, Esquivel B, Donaldson M. Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of Big Data. Pharmacogenomics 2020; 21(2), 141–156. doi:10.2217/pgs-2019-0134


        2019.

  1. Jeleč Ž, Primorac D, Antičević D. Personalized surgery approach in severe form of osteogenesis imperfecta type III: point of view. J Pediatr Orthop B. 2019 Sep;28(5):505-508
  2. Vuk-Pavlović S, Schanfield M, Primorac D. Into the third decade: eleventh ISABS Conference on Forensic and Anthropological Genetics and Mayo Clinic Lectures in Individualized Medicine. Croat Med J. 2019; 13;60(3):189-190
  3. Rod E, Matić I, Antunović M, Vetma V, Pavičić I, Hudetz D, Marijanović I, Primorac D, Ivković A. Optimization of an ex vivo gene transfer to the hamstrings tendons muscle remnants: potential for genetic enhancement of bone healing. Croat Med J. 2019 Jun 13;60(3):201-211.
  4. Ašić A, Salazar R, Storm N, Doğan S, Höppner W, Marjanović D, Primorac D. Population study of thrombophilic markers and pharmacogenetic markers of warfarin prevalence in Bosnia and Herzegovina. Croat Med J. 2019 Jun 13;60(3):212-220.
  5.  Hudetz D, Borić I, Rod E, Jeleč Ž, Kunovac B, Polašek O, Vrdoljak T, Plečko M, Skelin A, Polančec D, Zenić L, Primorac D. Early results of intra-articular micro-fragmented lipoaspirate treatment in patients with late stages knee osteoarthritis: a prospective study. Croat Med J. 2019 Jun 13;60(3):227-236.
  6. Bedalov A, Bašić Ž, Marelja I, Dolić K, Bukarica K, Missoni S, Šlaus M, Primorac D, Andjelinović Š, Kružić I. Sex estimation of the sternum by automatic image processing of multi-slice computed tomography images in a Croatian population sample: a retrospective study. Croat Med J. 2019 Jun 13;60(3):237-245
  7. Turkalj M, Matišić V, Šimić A, Juginović A, Erceg D, Tješić Drinković D, Höppner W, Primorac D. Cystic fibrosis presentation in del. F508 and p. Tyr109Glyfs compound heterozygote CFTR state: a case report. Croat Med J. 2019 Jun 13;60(3):246-249.
  8. Mandac Rogulj I, Matišić V, Arsov B, Boban L, Juginović A, Molnar V, Primorac D. Dasatinib-induced nephrotic syndrome: a case of phenoconversion. Croat Med J. 2019 Jun 13;60(3):250-254.
  9. Polancec D, Zenic L, Hudetz D, Boric I, Jelec Z, Rod E, Vrdoljak T, Skelin A, Plecko M, Turkalj M, Nogalo B, Primorac D. Immunophenotyping of a Stromal Vascular Fraction from Microfragmented Lipoaspirate Used in Osteoarthritis Cartilage Treatment and Its Lipoaspirate Counterpart. Genes (Basel). 2019 Jun 21;10(6). pii: E474. doi: 10.3390/genes10060474.
  10. Borić I, Hudetz D, Rod E, Jeleč Ž, Vrdoljak T, Skelin A, Polašek O, Plečko M, Trbojević-Akmačić, Lauc G, Primorac D. A 24-Month Follow-Up Study of the Effect of Intra-Articular Injection of Autologous Microfragmented Fat Tissue on Proteoglycan Synthesis in Patients with Knee Osteoarthritis. Genes 2019, 10(12), 1051; https://doi.org/10.3390/genes1... (registering DOI)
  11. Primorac D, Bach-Rojecky L, Vađunec D, Juginović A, Žunić K, Matišić V, Mikula I, Skelin A,  Arsov B, Boban L, Erceg D, Erceg Ivkošić I, Molnar V, Ćatić J, Boban Lj,  Esquivel B, Donaldson M. Pharmacogenomics at the center of precision medicine - challenges and perspective in an era of Big Dana (Pharmacogenomics In Press)
  12. Kubat O, Vlaić J, Antičević D. Knee orthopedic problems in newborns and infancy: a review. Curr Opin Pediatr. 2019;34(00). doi: 10.1097/MOP.0000000000000859.
  13. Boric I, Isaac A, Dalili D, Ouchinsky M, De Maeseneer M, Shahabpour M. Imaging of Articular and Extra-articular Sports Injuries of the Hip. Semin Musculoskelet Radiol. 2019 Jun;23(3):e17-e36. doi: 10.1055/s-0039-1688696. Epub 2019 Jun 4.
  14. Bach-Rojecky L, Vađunec D, Lozić M, Žunić K, Špoljar GG, Čutura T, Erceg D, Primorac D. Challenges in anesthesia personalization: resolving the pharmacogenomic puzzle. Per Med. 2019 Nov;16(6):511-525. doi: 10.2217/pme-2019-0056.

    2018.
  15. 1. Gudelj I, Salo PP, Trbojević-Akmačić I, Albers M, Primorac D, Perola M, Lauc G. Low galactosylation of IgG associates with higher risk for future diagnosis of rheumatoid arthritis during 10 years of follow-up. Biochim Biophys Acta. 2018 Mar 20. pii: S0925-4439(18)30098-X. doi: 10.1016/j.bbadis.2018.03.018
  16. Ašić A, Marjanović D, Mirat J, Primorac D. Pharmacogenetics of novel oral anticoagulants: A review of identified gene variants and future perspectives. Personalised Medicine. 2018;15(3):209-221.
  17. Trbojević-Akmačić I, Vučković F, Vilaj M, Skelin A, Karssen LC, Krištić J, Jurić J, Momčilović A, Šimunović J, Mangino M, De Gregori M, Marchesini M, Dagostino C, Štambuk J, Novokmet M, Rauck R, Aulchenko YS, Primorac D, Kapural L, Buyse K, Mesotten D, Williams FMK, van Zundert J, Allegri M, Lauc G. Plasma N-glycome composition associates with chronic low back pain. Biochim Biophys Acta Gen Subj. 2018;1862(10): 2124-2133.
  18. Bach-Rojecky L, Vandunec D, Zunic K, Kurija J, SIpicki S, Gregg R, Mikula I, Primorac D. Continuing war on pain: a personalised approach to the therapy with nonsteroidal anti-inflamatory drugs and opioids. Per Med 2018 Nov 28. doi: 10.2217/pme-2018-0116

    2017.
  19. Dagostino C, De Gregori M, Gieger C, Manz J, Gudelj I, Lauc G, Divizia L, Wang W, Sim M, Pemberton IK, MacDougall J, Williams F, Van Zundert J, Primorac D, Aulchenko Y, Kapural L, Allegri M; PainOmics Group. Validation of standard operating procedures in a multicenter retrospective study to identify -omics biomarkers for chronic low back pain. PLoS One. 2017 May 1;12(5):e0176372. doi: 10.1371/journal.pone.0176372.
  20. Hudetz D, Boric I, Rod E, Jeleč Ž, Radić A, Vrdoljak T, Skelin A, Lauc G, Trbojević Akmačić I, Plečko M, Polašek O, Primorac D. The Effect of Intra-articular Administration of Autologous Microfragmented Fat Tissue with Adipose-derived Mesenchymal Stem Cells on Proteoglycan Synthesis in Patients with Knee Osteoarthritis. Genes. 2017;8(10):270; doi:10.3390/genes8100270.

    2016.
  21. Freidin MB, Lauc G, Allegri M, Primorac D, Williams FM. Using omics in chronic pain conditions to delineate mechanisms and provide new therapeutic strategies. Pain Management. 2016;6(3):211-5.
  22. Compagnone C, Schatman ME, Rauck RL, Van Zundert J, Kraus M, Primorac D, Williams F, Allegri M, Saccani Jordi G, Fanelli G; Pain-Omics Group. Past, Present, and Future of informed consent in pain and genomics research: Challenges facing Global Medical Community. Pain Practice. 2016. Aug 26. doi: 10.1111/papr.12485.
  23. Pagani L, Lawson DJ, Jagoda E, Mörseburg A, Eriksson A, Mitt M, Clemente F, Hudjashov G, DeGiorgio M, Saag L, Wall DJ, Cardona A, Mägi R, Wilson Sayres AM, Kaewert S, Inchley C, Scheib LC, Järve M, Karmin M, Jacobs SG, Antao T, Mircea Iliescu F, Kushniarevich A, Ayub Q, Tyler-Smith C, Xue Y, Yunusbayev B, Tambets K, Basu Mallick C, Saag L, Pocheshkhova E, Andriadze G, Muller C, Westaway CM, Lambert MD, Zoraqi G, Turdikulova S, Dalimova D, Sabitov Z, Sultana GNN, Lachance J, Tishkoff S, Momynaliev K, Isakova J, Damba LD, Gubina M, Nymadawa P, Evseeva I, Atramentova L, Utevska O, Ricaut FX, Brucato N, Sudoyo H, Letellier T, Cox PM, Barashkov AN, Skaro V, Mulahasanovic L, Primorac D, Sahakyan H, Mormina M, Eichstaedt AC, Lichman VD, Abdullah S, Chaubey G, Wee TSJ, Mihailov E, Karunas A, Litvinov S, Khusainova R, Ekomasova N, Akhmetova V, Khidiyatova I, Marjanović D, Yepiskoposyan L, Behar MD, Balanovska E, Metspalu A, Derenko M, Malyarchuk B, Voevoda M, Fedorova AS, Osipova PL, Mirazón Lahr M, Gerbault P, Leavesley M, Migliano BA, Petraglia M, Balanovsky O, Khusnutdinova KE, Metspalu E, Thomas GM, Manica A, Nielsen R, Villems R, Willerslev E, Kivisild T, Metspalu M. Genomic analyses inform on migration events during the peopling of Eurasia. Nature. 2016 Sep 21;538(7624):238-242.
  24. Allegri M, De Gregori M, Minella CE, Klersy C, Wang W, Sim M, Gieger C, Manz J, Pemberton IK, MacDougall J, Williams FM, Van Zundert J, Buyse K, Lauc G, Gudelj I, Primorac D, Skelin A, Aulchenko YS, Karssen LC, Kapural L, Rauck R, Fanelli G; PainOMICS Group. “Omics” biomarkers associated with chronic low back pain: Protocol and retrospective longitudinal study. BMJ Open. 2016 Oct 19;6(10):e012070. doi: 10.1136/bmjopen-2016-012070.

    2015.
  25. Karmin M, Saag L, Vicente M, Sayres MA, Järve M, Talas UG, Rootsi S, Ilumäe AM, Mägi R, Mitt M, Pagani L, Puurand T, Faltyskova Z, Clemente F, Cardona A, Metspalu E, Sahakyan H, Yunusbayev B, Hudjashov G, DeGiorgio M, Loogväli EL, Eichstaedt C, Eelmets M, Chaubey G, Tambets K, Litvinov S, Mormina M, Xue Y, Ayub Q, Zoraqi G, Korneliussen TS, Akhatova F, Lachance J, Tishkoff S, Momynaliev K, Ricaut FX, Kusuma P, Razafindrazaka H, Pierron D, Cox MP, Sultana GN, Willerslev R, Muller C, Westaway M, Lambert D, Skaro V, Kovačevic L, Turdikulova S, Dalimova D, Khusainova R, Trofimova N, Akhmetova V, Khidiyatova I, Lichman DV, Isakova J, Pocheshkhova E, Sabitov Z, Barashkov NA, Nymadawa P, Mihailov E, Seng JW, Evseeva I, Migliano AB, Abdullah S, Andriadze G, Primorac D, Atramentova L, Utevska O, Yepiskoposyan L, Marjanovic D, Kushniarevich A, Behar DM, Gilissen C, Vissers L, Veltman JA, Balanovska E, Derenko M, Malyarchuk B, Metspalu A, Fedorova S, Eriksson A, Manica A, Mendez FL, Karafet TM, Veeramah KR, Bradman N, Hammer MF, Osipova LP, Balanovsky O, Khusnutdinova EK, Johnsen K, Remm M, Thomas MG, Tyler-Smith C, Underhill PA, Willerslev E, Nielsen R, Metspalu M, Villems R, Kivisild T. A recent bottleneck of Y chromosome diversity coincides with a global change in culture. Genome Res. 2015; 25(4):459-466.
  26. Gudelj I, Keser T, Vučković F, Škaro V, Goreta SŠ, Pavić T, Dumić J, Primorac D, Lauc G, Gornik O. Estimation of human age using N-glycan profiles from bloodstains. Int J Legal Med. 2015.
  27. Tominac Trcin M, Dekaris I, Mijović B, Bujić M, Zdraveva E, Dolenec T, Pauk-Gulić M, Primorac D, Crnjac J, Špoljarić B, Mršić G, Kuna K, Špoljarić D, Popović M. Synthetic vs natural scaffolds for human limbal stem cells. Croat Med J. 2015; 19;56(3):246-56.
  28. Bašić Ž, Fox AR, Anterić I, Jerković I, Polašek O, Anđelinović Š, Holland MM, Primorac D. Cultural inter-population differences do not reflect biological distances: an example of interdisciplinary analysis of populations from Eastern Adriatic coast. Croat Med J. 2015;19;56(3):230-8.
  29. Mikula, Ivan; Bošnjak Pašić, Marija. Nerve lesions in knee dislocations. Journal of the Neurological Sciences 2015. 357: 246.

Articles published in journals listed in other scientific indexes:

       2020.

  1. Jeleč Ž, Gjurašin T, Pirkl AV, Rujevčan G. Extraction of the Proximal Phalanx: A New Option in Surgical Treatment of the Crossover Second Toe. Case Reports in Orthopedics. 2020. doi: 10.1155/2020/3901458.

    2019.
  2. Antičević D, Kubat O. Pathological fractures of the femoral neck. Giornale Italiano di Ortopedia e Traumatologia 2019;45 (Suppl.):S238-S242.
  3. Pavlović T, Štefančić K, Rožanković M, Boban L, Borić I, Molnar V, Zekan P, Primorac D. Ventrolateral disc herniation causes psoas muscle compression: A case report. Radiol Case Rep. 2019 Nov 27;15(2):136-140. doi: 10.1016/j.radcr.2019.10.031.
  4. Primorac D and Bach-Rojecky L. Could a Personalized Approach to Therapy End the war on Pain? Practical Pain Management. 2019 19;3:50-53.

    2018.
  5. Plečko M, Hudetz D, Primorac D. Novel Cell-Based Techniques in Management of Osteoarthritis Nov Tech Arthritis Bone Res 2(5): NTAB.MS.ID.555598 (2018)
  6. Vlaić J, Bojić D, Antičević D. Congenital spondylo-epyphyseal dyspasia – surgical treatment of varus deformities of the hip join. Paediatr Croat 2018;4:180.
  7. Polančec D, Zenić L, Hudetz D, Borić I, Jeleč Ž, Rod E, Vrdoljak T, Skelin A, Plečko M, Turkalj M, Nogalo B, Primorac D. Immunophenotyping of stromal vascular fraction from microfragmented adipose tissue and and lipoaspirate from patients with osteoarthritis. Paediatr Croat. 2018; 62:171.
  8. Primorac D, Hudetz D, Borić I, Jeleč Ž, Rod E, Vrdoljak T, Lauc G, Skelin A Polančec D, Zenić L, Trbojević-Akmačić I, Nogalo B, Turkalj M, Plečko M, Polašek O. Cell therapy in treatment of cartilage tissue defects: Experiences from St. Catherine Specialty Hospital. Paediatr Croat. 2018; 62:167-168.
  9. Rod E, Matić I, Antunović M, Vetma V,Pavičić I, Hudetz D, Marijanović I, Primorac D, Ivković A. Optimization of genetic (ex vivo) therapy with bon morphogenic protein-2 in reconstruction of anterior cruciate ligament of the knee. Paediatr Croat. 2018; 62:172.
  10. Ćatić J, Skelin A, Boban L, Molnar V, Matišić V, Zekan P, Arson B, Juginović A, Mikula I, Bach-Rojecky L, Erceg-Ivkošić I, Erceg D, Primorac D. Multimodal concept of pharmacogenomic testing in clinical practice: St Catherine Specialty Hospital and OneOme model. Paediatr Croat. 2018; 62:174.
  11. Bach-Rojecky L, Vađunec D, Žunić K, Kurija J, Mikula I, Primorac D. Pharmacogenomics in pain treatment. Paediatr Croat. 2018; 62:173.
  12. Marjanović D, Havaš D, Šarac J, Missoni S, Primorac D. Newest trends in human identification. Paediatr Croat. 2018; 62:183.
  13. Boban Lj, Primorac D. Diagnosis and treatment of Osteogenesis Imperfecta – Personalized approach. Paediatr Croat. 2018; 62:178.

    2017.
  14. Boban Lj, Rod E, Plečko M, Slišković AM, Korbler J, Primorac D. Molecular basis of osteogenesis imperfecta and future medical treatment. Paediatr Croat. 2017; 61:147-55.
  15. Stubbe A, Primorac D, Hoppner W. Molecular genetic analysis of Osteogenesis Imperfeca in clinical practice. Paediatr Croat. 2017; 61:141-6.
  16. Barišić I, Turkalj M, Primorac D. Osteogenesis Imperfecta: clinical assessment and medical treatment. Paediatr Croat. 2017; 61:97-105.
  17. Turkalj M, Miranović V, Lulić-Jurjević R, Gjergja Juraški R, Primorac D. Cardiorespiratory complications in patients with Osteogenesis Imperfecta. Paediatr Croat. 2017; 61:106-12.
  18. Gjergja Juraški R, Turkalj M, Mikula I, Primorac D. Neurologic manifestations and sleep issues in Osteogenesis Imperfecta. Paediatr Croat. 2017; 61:113-21.
  19. Antičević D, Jeleč Ž. Osteogenesis imperfecta: surgical treatment options with emphasis on today’s orthopedic approach – review. Paediatr Croat. 2017;61:129-33.   doi.org/10.13112/PC.2017.18

    2016.
  20. Houra K, Perović D, Hudetz D, Radić A, Rod E, Borić I, Prpić Vučković R, Skok I, Granec D; Mikula I, Skelin A, Lauc G, Škaro V, Primorac D. Personalized medicine in modern radiology, neurology, neurosurgery, orthopaedics, anaesthesiology, physical medicine and rehabilitation and paediatrics: model of St. Catherine's Hospital. Paediatr Croat. 2016; 60 (Supl 1): 1-17
  21. Miškov, Snježana; Gjergja Juraški, Romana: Mikula, Ivan; Bašić , Silvio; Bošnjak Pašić, Marija; Košec, Vesna; Sabol, Zlatko; Fučić, Aleksandra; Sajko, Tomislav i Bašić Kes, Vanja. The Croatian model of integrative prospective management and pregnancy. Acta Clin Croat 2016; 55:535-548

Books and Contributions to Books:

      2020.

  1. Mikula I, Vukasović I. Medical-biochemical diagnostics in neurology In: Topić E, Primorac D, Janković S, Štefanović M, urednici i sur. Medical chemistry and laboratory medicine in clinical practice. Zagreb: Medicinska naklada; 2018. Pages 238-272.

    2019.
  2. Hudetz D, Jeleč Ž, Rod E, Borić I, Plečko M, Primorac D. The Future of Cartilage Repair. In: Personalized Medicine in Healthcare Systems: legal, Medical and Economic Implications. (Editors: Nada Bodiroga-Vukobrat, Daniel Rukavina, Krešimir Pavelić, Gerald G. Sander). Springer Nature Switzerland, Switzerland, 2019
  3. Borić I, Pećina M, Mirković M, Cicvara Pećina T, Matoković D, Plečko M, Dumić-Čule I. Hallux Sesamoiditis - Radiological Diagnostics and Conservative Management. RAD 540. Medical Sciences 48-49 (2019): 27-32. https://doi.org/10.21857/ m8vqrtzxg9.

    2018.
  4. Topić E, Primorac D, Janković S, Štefanović M, editors. Medical Biochemistry and Laboratory Medicine in Clinical Practice. 2nd ed. Zagreb: Medicinska naklada; 2018.
  5. Marjanović D, Primorac D, Dogan Serkan: Forensic genetics: Theory and Application., International Burch University, Sarajevo, 2018.
  6. Erceg Ivkošić I, Bauman R, Hafner D, Sirovec A, Pavelić Turudić T. Diagnostics of infertility. In: Topić E, Primorac D, Janković S, Štefanović M, urednici i sur. Medical chemistry and laboratory medicine in clinical practice. Zagreb: Medicinska naklada; 2018. Pages 598-608.
  7. Rod E, Plečko M, Slišković AM, Borić I, Hudetz D, Jeleč Ž, Skelin A, Lauc G, Trbojević-Akmačić I, Polašek O, Vrdoljak T, Primorac D. Application od microfragmented adipose tissue with stromal vascular fraction in treatment of damaged joint cartilage: Experience from physicians of St. Catherine Specialty Hospital. In: Molecular genetics: news in diagnostics and treatment. (Editors: Jadranka Sertić, Stjepan Gamulin, Filip Sedlić). Zagreb: Medicinska naklada; 2018. p. 28-48.
  8. Kunovac B, Hudetz D, Rod E, Jeleč Ž, Vrdoljak T, Borić I, Čutura T, Gasparini Špoljar Giorgina, Primorac D. Regenerative medicine and new paradigm in treatment of damaged cartilage tissue. In: Applied genomics – precision medicine. Zbornik znanstvenog sastanka, Zagreb, 23. listopada 2018. (stranice 1-9)

    2016.
  9. Höppner W and Primorac D. Pharmacogenetics in clinical practice Experience with 16 commonly used drugs. St. Catherine Hospital, Zagreb, Berlin, Hamburg, 2016

    2015.
  10. Mikula I, Skelin A, Primorac D. Physiology, biochemistry and genetics of dopamine. Dopamine in health and disease – myths and facts. Jakovljević M (Ed.), Zagreb, Pro Mente, 2015; 82-99.

Abstracts:

      2019.

  1. Erceg Ivkošić Ivana: Infertilty and pelvic Health, CSP (Croatian Society for Pelviperineology) 2nd Annual Congress with International Participation / and CSP 1st Postgraduate Course on Pelviperineology and Pelvic Health, Hotel Terme Jezerčica, Donja Stubica, Croatia, December 6th - 8th, 2019.
  2. Antičević D, Jeleč Ž, Primorac D. Prolonged bisphosphonates treatment and telescoping implants in OI – Is there synergy? 11th ISABS Conference on Forensic and Anthropology Genetics and 7th Croatian Congress of Human Genetics, June 17-22. 2019, Split, Croatia. Book of abstracts, page 327.
  3. Ašić A, Salazar R, Storm N, Doğan S, Höppner W, Marjanović D, Primorac D. Population study of thrombophilic markers and pharmacogenetic markers of warfarin prevalence in Bosnia and Herzegovina. 11th ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine. Split, Croatia, June 17-22, 2019 (Book of abstracts, page 132).
  4. Matišić V, Šimić A, Turkalj M, Juginović A, Erceg D, Tješić Drinković D, Höppner W, Primorac D. Cystic fibrosis presentation in del. F508 and p. Tyr109glyfs compound heterozygote CFTR state: case report. 11th ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine. Split, Croatia, June 17-22, 2019 (Book of abstracts, page 152).
  5. Ašić A, Salazar R, Storm N, Doğan S, Höppner W, Marjanović D, Primorac D. Prevalence of rare F5 variants in general population from Bosnia and Herzegovina. 11th ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine. Split, Croatia, June 17-22, 2019 (Book of abstracts, page 154).
  6. Vađunec D, Juginović A, Žunić K, Matišić V, Arsov B, Molnar V, Boban L, Bach-Rojecky L, Skelin A, Erceg D, Erceg Ivkošić I, Esquivel B, Donaldson M, Primorac D. Pharmacogenomics at the center of personalized medicine - challenges and perspective in the developing world of artificial intelligence. 11th ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine. Split, Croatia, June 17-22, 2019 (Book of abstracts, page 178).
  7.  Žunić K, Vađunec D, Lozić M, Bach-Rojecky L, Gasparini G, Čutura T, Erceg D, Primorac D. Challenges in anesthesia personalization - resolving the pharmacogenomic puzzle. 11th ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine. Split, Croatia, June 17-22, 2019 (Book of abstracts, page 184).
  8. Vađunec D, Žunić K, Bach-Rojecky L, Mikula I, Primorac D, Donaldson M, Esquivel B. Personalization of pain therapy – a role for pharmacogenomics. 11th ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine. Split, Croatia, June 17-22, 2019 (Book of abstracts, page 186).
  9. Arsov B, Juginović A, Matišić V, Mandac Rogulj I, Molnar V, Boban L, Primorac D. Dasatinib induced nephrotic syndrome: a case of phenoconversion or? 11th ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine. Split, Croatia, June 17-22, 2019 (Book of abstracts, page 190).
  10. Juginovic A, Erceg D, Boban L, Matisic V, Molnar V, Arsov B, Primorac D. Life-saving potential of pharmacogenomics. 11th ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine. Split, Croatia, June 17-22, 2019 (Book of abstracts, page 191).
  11. Polančec D, Zenić L, Hudetz D, Borić I, Jelec Z, Rod E, Vrdoljak T, Skelin A, Plečko M, Turkalj M, Nogalo B, Primorac D. Polychromatic flow cytometry immunophenotyping of microfragmented lipoaspirate therapeuticaly used in osteoarthritic patients. 11th ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine. Split, Croatia, June 17-22, 2019 (Book of abstracts, page 214).
  12. Mikula I. Case report – statin-induced ‘double-hit’ – myositis and myopathy in a genetically predisposed patient. 11th ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine. Split, Croatia, June 17-22, 2019 (Book of abstracts, page 179).

    2018.
  13. Hudetz D, Borić I, Jeleč Ž, Rod E, Primorac D. Increase in proteoglycan synthesis after intraarticular injection of autologous micro-fragmented fat tissue in knee osteoarthritis (#PO3-1030). 18th ESSKA Congress, Glasgow, May 9-12, 2018.
  14. Hudetz D, Borić I, Rod E, Jeleč Ž, Vrdoljak T, Primorac D. Paradigm shift in treating osteoarthritis pain: Personalized medicine approach. 4th Croatian Congress on the treatment of pain with international participation. (Endorsed by European Pain Federation). Osijek, Republic of Croatia, May 18th, 2018.
  15. Berić-Lerotić S, Čutura T, Primorac D, Mikula I. Multimodal approach to the treatment of chronic pain. First Mediterranean Symposium on Comprehensive Joint Care. Split, Croatia, October 5-7, 2018 (Book of abstracts, page 49)
  16. Polančec D, Zenić L, Hudetz D, Borić I, Jeleč Ž, Rod E, Vrdoljak T, Skelin A, Plečko M, Turkalj M, Nogalo B, Primorac D. The difference between stromal vascular fraction cell content in Lipogems product compared to the lipoaspirate counterpart. First Mediterranean Symposium on Comprehensive Joint Care. Split, Croatia, October 5-7, 2018 (Book of abstracts, page 50)
  17. Borić I, Hudetz D, Jeleč Ž, Rod E, Plečko M, Vrdoljak T, Skelin A, Lauc G, Trbojević-Akmačić I, Čukelj F, Polašek O, Primorac D. Two-year follow-up of the effect of intra-articular injection of autologous microfragmented fat tissue on proteoglycan synthesis in patients with knee osteoarthritis. First Mediterranean Symposium on Comprehensive Joint Care. Split, Croatia, October 5-7, 2018 (Book of abstracts, page 51)
  18. Hudetz D, Borić I, Jeleč Ž, Rod E, Plečko M, Vrdoljak T, Skelin A, Polašek O, Primorac D. Effectiveness of autologous microfragmented fat tissue on knee osteoarthritis: one year follow-up. First Mediterranean Symposium on Comprehensive Joint Care. Split, Croatia, October 5-7, 2018 (Book of abstracts, page 52)
  19. Bach-Rojecky L, Vađunec D, Žunić K, Kurija J, Šipicki S, Mikula I, Gregg RA, Primorac D. Pharmacogenomics (pgx) and epigenetics in pain management. First Mediterranean Symposium on Comprehensive Joint Care. Split, Croatia, October 5-7, 2018 (Book of abstracts, page 53)

    2017.
  20. Hudetz D, Rod E, Vrdoljak T, Borić I, Primorac D. One year clinical experience with Lipogems in treating musculoskeletal disorders-Hip, knee and Achilles tendon. Lipogems day: Regenerative medicine in orthopedics. Warsaw, Poland, March 23-24, 2017.
  21. Hudetz D, Rod E, Vrdoljak T, Borić I, Primorac D. One year clinical experience with Lipogems in treating musculoskeletal disorders-Hip, knee and Achilles tendon. Lipogems day: Regenerative medicine in orthopedics. Warsaw, Poland, March 23-24, 2017.
  22. Hudetz D, Borić I, Rod E, Jeleč Ž, Radić A, Vrdoljak T, Sklein A, Lauc G, Trbojević Akmačić I, Plečko M, Polašek O, Primorac D. A year follow-up study of AdMSC therapy in patients with knee osteoarthritis. 10th ISABS Conference of Forensic and Anthropological Genetics and Mayo Clinic Lectures in Individualized Medicine, Dubrovnik June 19-24, 2017. Book of abstracts page 203.
  23. Höppner W, Antičević D, Jeleč Ž, Stubbe S, Salazar S, Rod E, Mićić S, Turkalj M, Hudetz D, Borić I, Radić A, Vrdoljak T, Rykunov A, Skok I, Čutura T. Prpić-Vučković, Primorac D. An interdisciplinary personalized medicine approach in diagnosis and treatment of patients with Osteogenesis Imperfecta Type 3. 10th ISABS Conference of Forensic and Anthropological Genetics and Mayo Clinic Lectures in Individualized Medicine, Dubrovnik June 19-24, 2017. Book of abstracts page 197.
  24. Rod E, Matić I, Antunović M, Marijanović I, Primorac D, Ivković A. Optimization of an Ex Vivo gene transfer to the hamstrings tendons muscle remnants: potential for genetic enhancement of bone-tendon healing. 10th ISABS Conference of Forensic and Anthropological Genetics and Mayo Clinic Lectures in Individualized Medicine, Dubrovnik June 19-24, 2017. Book of abstracts page 218.

    2015.
  25. Marjanović D, Hadžić N, Čakar J, Džehverović M, Škaro V, Projić P, Džijan S, Dogan S, Primorac D. The Ninth ISABS Conference on Forensic, Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine. Bol, Island of Brač, Croatia, June 22-26, 2015 (Book of abstracts, page 47)
  26. Primorac D. Genetic History of Croatia. The Ninth ISABS Conference on Forensic, Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine. Bol, Island of Brač, Croatia, June 22-26, 2015 (Book of abstracts, page 56)
  27. Crnjac J, Merkaš S, Rožić S, Sukser V, Špoljarić D, Popović M, Anđelinović Š, Primorac D, Mršić G. The Ninth ISABS Conference on Forensic, Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine. Bol, Island of Brač, Croatia, June 22-26, 2015 (Book of abstracts, page 112)
  28. Borić I, Sutlović D, Vučinović A, Nikolić I, Slišković L, Knezović Z, Vučinović Z, Šlaj M, Primorac D. The Ninth ISABS Conference on Forensic, Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine. Bol, Island of Brač, Croatia, June 22-26, 2015 (Book of abstracts, page 121)
  29. Matić T, Kušec R, Primorac D, Rahelić D, Romić Ž, Lauc G, Božikov V. Single Nucleotide polymorphisms of fto and sparc genes in obese patients. The Ninth ISABS Conference on Forensic, Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine. Bol, Island of Brač, Croatia, June 22-26, 2015 (Book of abstracts, page 201)
  30. Tominac Trcin M, Dekaris I, Mijovic B, Bujic M, Zdraveva E, Dolenec T, Puk-Gulic M, Mrsic G, Primorac D, Kuna K, Popovic M. The Ninth ISABS Conference on Forensic, Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine. Bol, Island of Brač, Croatia, June 22-26, 2015 (Book of abstracts, page 228)

    2013.
  31. Risso E, Primorac D. Airbag injuries in transportation pathology. American Academy of Forensic Sciences 65th Meeting. Washington, DC, USA, February 18-23, 2013 (Books of abstracts, page 341, #G84)
  32. Risso E, Primorac D. Autonomic nervous system and sudden death. American Academy of Forensic Sciences 65th Meeting. Washington, DC, USA, February 18-23, 2013 (Books of abstracts, page 361, #G11)
  33. Risso E, Anđelinović Š, Primorac D. Toxicology of the exhumed body: Challenges and pitfalls. American Academy of Forensic Sciences 65th Meeting. Washington, DC, USA, February 18-23, 2013 (Books of abstracts)
  34. Primorac D, Mance M, Anđelinović Š, Letica S. Death of Ivica Kugli: Ethical, medical and legal reasons and the need for forensic analysis of the remains of a high school student buried in 1945. The Eight ISABS Conference on Forensic, Anthropologic and Medical Genetics and Mayo Clinic Lectures in Translational Medicine. Split, Croatia, June 24-28, 2013 (Book of abstracts, page 333).
  35. Novokmet M, Thanabalasingham G, Huffman J, Rudan I, Primorac D, Wright A, Campbell H, Owen K, McCarthy M, Lauc G. Optimal sample choice for analysis of protein antennary fucosylation as screening tool for HNF1A-MODY. The Eight ISABS Conference on Forensic, Anthropologic and Medical Genetics and Mayo Clinic Lectures in Translational Medicine. Split, Croatia, June 24-28, 2013 (Book of abstracts, page 325).
  36. Fatur-Ceric V, Kovacevic L, Hadzic N, Cakar J, Primorac D, Marjanovic D. Polymorphism of six new Y chromosome STR loci (DYS576, DYS481, DYS549, DYS533, DYS570, DYS643) in referent sample of Bosnia and Herzegovina. The Eight ISABS Conference on Forensic, Anthropologic and Medical Genetics and Mayo Clinic Lectures in Translational Medicine. Split, Croatia, June 24-28, 2013 (Book of abstracts, page 176).
  37. Gršković B, Zidkova A, Stenzl V, Popović M, Primorac D, Mršić G. Genetic characterization of central Croatia population using MENTYPE Argus X-8 kit. The Eight ISABS Conference on Forensic, Anthropologic and Medical Genetics and Mayo Clinic Lectures in Translational Medicine. Split, Croatia, June 24-28, 2013 (Book of abstracts, page 170).
  38. Primorac D, Lauc G, Rudan I. Predicting age from biological markers in forensic traces. The Eight ISABS Conference on Forensic, Anthropologic and Medical Genetics and Mayo Clinic Lectures in Translational Medicine. Split, Croatia, June 24-28, 2013 (Book of abstracts, page 66).

 

Invited lectures:

       2020.

  1. Primorac D. “Bringing Personalized Medicine into Clinical Practice: Model of St. Catherine Hospital”. Zagreb, Croatia. BICRO and Ministry of Foreign Affairs of the Republic of Croatia. January 10th, 2020.

    2019.
  2. D. Primorac. The Future of University Education in 22nd Century. University of Mostar, Bosnia and Herzegovina, January 16th, 2019.
  3. D. Primorac. Forensic DNA Analysis: Past, Present and Future. University of Mostar, Bosnia and Herzegovina, January 16th, 2019.
  4. D. Primorac. Regenerative Medicine: Myth or Reality. University of Mostar School of Medicine, Bosnia and Herzegovina, January 17th, 2019.
  5. D. Primorac. The Future of Personalized Medicine. Health City Berlin. Berlin, Germany, January 24th, 2019.
  6. D. Primorac. Molecular Genetics: The Present and the Future. The 2nd International Symposium “Vera Johanides”-Biotechnology in Croatia by 2020. Croatian Academy of Technical Sciences. Zagreb, Croatia, May 10-11 2013.
  7. D. Primorac. Progress of innovation and medicine in the USA - Is Europe left behind? the European Health Congress, Munich, September 27, 2019.
  8. D. Primorac. Personalised medicine: Model of the St. Catherine Specialty Hospital, Ministry of Economy of the Republic of Croatia, Zagreb, October 25th,
  9. D. Primorac. Osteoarthritis treatment and future of cartilage regeneration. Swiss Pain Congress, Montreux, Switzerland, November 29-30, 2019.
  10. I Erceg Ivkošić, E Radončić, M Ćurlin: Tribina “Oh! Family; in-vitro fertilization – natural family planning”, Cycle of public debates of the Zagreb Faculty of Phylosophy, in organization of Virtus Society. May 22nd, 2019. Faculty of Phylosophy. Zagreb, Croatia
  11. I Erceg Ivkošić. Infertilty and pelvic Health, CSP (Croatian Society for Pelviperineology) 2nd Annual Congress with International Participation / CSP 1st Postgraduate Course on Pelviperineology and Pelvic Health, Hotel Terme Jezerčica, Donja Stubica, Croatia, December 6th - 8th, 2019.
  12. I. Boric. Knee Injury Diagnostics. Muscles Lab. Zagreb, Croatia. February 9th, 2019.
  13. I. Boric Anatomy & imaging of common shoulder pathologies in sport. South East European Forumon Orthopaedics and Traumatology. Dubrovnik, Croatia. April 24th-26th, 2019.
  14. I. Boric. Anatomy & imaging of common elbow pathologies in sport. South East European Forumon Orthopaedics and Traumatology. Dubrovnik, Croatia. April 24th-26th, 2019.
  15. I. Boric. CT/MR in the muskuloskeletal system. CT-MR of the body. Rijeka, Croatia. May 2nd-4th, 2019.
  16. I. Boric. Correlation of ultrasound and MR in shoulder pathologic conditions. 6th Croatian-Slovenian Ultrasound Congress 2019. Vodice, Croatia. May 9th-11th, 2019.
  17. I. Boric. Specificity of sports related elbow and wrist injuries. European Congress of Musculoskeletal Radiology. Lisbon, Portugal. June 27th-29th, 2019.
  18. I. Boric. MR diagnostics of calcifying tendinopathy. Calcifying Tendinopathy Symposium. Zagreb, Croatia. September 30th, 2019.
  19. I. Boric. Anterior knee pain. Munich Sports Imaging Conference. Munich, Germany. October 11th-12th, 2019.
  20. I. Boric. New techniques in diagnosis of degenerated disc. Croatian Vertebrology Society. Zagreb, Croatia. October 16th, 2019.
  21. I. Boric. Radiologic methods of diagnosing sports injuries. Croatian Radiology Society. Zagreb, Croatia. October 17th, 2019.
  22. I. Boric. What can radiologist tell us about shoulder?. Shoulder À la Carte. Zagreb, Croatia. October 26th, 2019.
  23. I. Boric. Anterior knee pain. Serbian Radiology Congress. Zlatibor, Serbia. October 31st – November 2nd, 2019.
  24. I. Boric. MR in locomotor system trauma. Radiology of emergency conditions - symposium. Zagreb, Croatia. November 29th, 2019.

    2018.
  25. D. Primorac.The Future of Cartilage Repair. Cell and Gene Therapy: Innovation Summit 2018. Berlin, Germany, February 7-8th, 2018.
  26. D. Primorac.Knee Pain and personalized medicine: What does the future look like: 4th Annual Meeting of The World Academy of Pain Medicine (WAPMU), Miami, USA, February 16-18th, 2018.
  27. D. Primorac.Research in Science: How Young Scientists Can Shape A Better Future. The Young Scientific Forum (YFSF), AAFS Annual Meeting, Seattle, WA, February 20, 2018
  28. D. Primorac. Call for Action: Transatlantic Scaling of Precision Medicine & Regenerative Medicine Prototypes and Pilotes for Value-based Healthcare towards a Precision Medicine Industry. Precision Medicine Alliance Conference, Leipzig, Germany, March 22, 2018
  29. D. Primorac.Intra-articular Injection of Autologous Microfragmented Fat in Osteoarthritis 9th World Congress of the World Institute of Pain (WIP 2018). Dublin, Ireland May 9-12, 2018.
  30. D. Primorac.Personalized Medicine for Cartilage Damage: Where Are We Now? International Conference on Personalized Medicine. Warsaw, Poland, March 5, 2018,
  31. D. Primorac. Paradigm shift in treating osteoarthritis pain: Personalized medicine approach. 4th Croatian Congress on the treatment of pain with international participation. (Endorsed by European Pain Federation). Osijek, Republic of Croatia, May 18th, 2018.
  32. D. Primorac. The Future of Cartilage Repair. The First Mediterranean Symposium of Comprehensive Joint care. (Endorsed by European Pain Federation). Split, Republic of Croatia, October 5-7, 2018.
  33. D. Primorac. Forensic DNA in the Legal System. Conference was organized by U.S. Department of Justice (OPDAT) and Serbian Supreme Court. Belgrade, Republic of Serbia, October 26, 2018.
  34. D. Primorac. Advance and Prospects in Stem Cells for Cartilage Regeneration. Annual meeting of The Croatian Society for Human Genetics. Zagreb, Republic of Croatia, December 8, 2018.

    2017.
  35. D. Primorac.The future of personalized medicine. Bridging education and best practice. Organized by University of Applied Health Sciences. Opatija, Croatia, March 20-21, 2017.
  36. D. Primorac.Regenerative medicine: A new approach to treatment. International Conference on Personalized Medicine. Organized by MEDILS and by Croatian Society for Human Genetics. Split, May 6, 2017.
  37. D. Primorac. Mesenchymal Stem Cell-Based Therapy for Cartilage Repair. 8th International Scientific Conference on Kinesiology. Organized by Faculty of Kinesiology, University of Zagreb, Croatia, Opatija, Croatia, May 10-14, 2017.
  38. D. Primorac.Personalized and Regenerative Medicines: a paradigm shift in healthcare. The 6th Croatian Diabetes Congress with International Participation and the 80th Days of Diabetologists, Poreč, Croatia, May 11-15, 2017.
  39. D. Primorac.Autologous Adipose-derived Mesenchymal Stem Cells Therapy in The Treatment of Osteoarthritis. 12th Balkan Congress of Human Genetics, Plovdiv, Bulgaria, September 8-10, 2017.
  40. D. Primorac.The future of personalized medicine. 16. Europäischer Gesundheitskongress München, Germany, October 12-13, 2017.
  41. D. Primorac. The Future of Forensic Genetic. Silk Road Forensic Consortium (SRFC) Conference, Xi’an, China, November 6-7, 2017.
  42. D. Primorac.Perspectives of adipose mesenchymal stem cells (AdMSCs) -based therapy for osteoarthritis (OA). Acute and General Medicine, London, UK, November 20-2017.
  43. D. Primorac.News in Osteoarthritis Treatment. Molecular Genetics-News in Diagnostics and Therapy. Croatian Academy of Sciences and Arts. Zagreb, Croatia, October 16 2017.
  44. D. Primorac.Molecular basis of Osteogenesis Imperfecta and future medical treatment. St. Catherine’s Symposium on Advanced Orthopedic Treatment of Osteogenesis Imperfecta. Zabok, Croatia, October 28, 2017.
  45. I. Mikula. Complications during rehabilitation of neuromuscular disorders. ERFF Doctorate course of category one. Zagreb, 2017.
  46. I. Mikula. Neurophysiological diagnostics of Craniocerebral Trauma. I Croatian Congress of Sports Medicine, Split, 2017.

    2016.
  47. D. Primorac.Big data in small data. Data science monetization. Zagreb, Croatia, April 13-14, 2016.
  48. D. Primorac. Cell therapy and regenerative medicine. Myth or reality. The 33rd Croatian Pediatrics School. Split, Croatia, April 18-22, 2016.
  49. D. Primorac.Human genetics – costs and benefits. International Union of Anthropological and Ethnological Science’s (IUAES) Inter-Congress World anthropologies and privatization of knowledge: engaging anthropology in public. Dubrovnik, Croatia, May 4-9, 2016.
  50. D. Primorac.Recent insights on Genetic Factors in Joint Pain. 1st The European Pain Federation (EFIC) Symposium on Acute and Chronic Joint Pain. Dubrovnik, Croatia, September 21-23, 2016
  51. D. Primorac.The Future of Regenerative Medicine. 2nd Croatian Healthcare Congress 2016. Zagreb, Croatia, October 25th, 2016.
  52. D. Primorac.The Past, Present and Future of Forensic Genetic. Frontier Symposium of Forensic Sciences. Xi’an, China, October 30-31, 2016.

    2015.
  53. D. Primorac. Estimation of Human Age Using N-Glycan Profiles From Bloodstains. American 67th Annual Meeting of the Academy of Forensic Sciences. Orlando, US, February 16-21, 2015.
  54. D. Primorac. The Future of Biomedical Science and Clinical Practice. Atopica conference. Seventh Framework Programme (Grant agreement # 282687). Brussels, March 5-6, 2015
  55. D. Primorac. Advances of Certified Clinics. 5th International Health Tourism Industry Conference. Krapinske Toplice, Croatia, March 12-14, 2015.
  56. D. Primorac. Personalized medicine: Myth or Reality? The First Conference of Medical and Biological Engineering in Bosnia and Herzegovina (CMBEBIH 2015), Sarajevo, March 13 – 15, 2015.
  57. D. Primorac. Ethics, Forensics and Pain Management. The Seventh SIMPAR meeting, Rome, Italy, March 27-28, 2015.
  58. D. Primorac. Genetics and pain. 6th Croatian Congress of Regional Anaesthesia and Analgesia with International Participation. June 12-13, 2015. Zagreb, Croatia.
  59. D. Primorac. Personalized and regenerative medicine: A myth or reality. The Conference on the future of healthcare industry (Styria). Zagreb, Croatia, October 20th, 2015.
  60. D. Primorac. Genetics and personalized medicine. The Sixth Conference of the Croatian Society of Human Genetics. Split, Croatia, October 5-7, 2015.
  61. I. Mikula. 2015. EMG, EEG and evoked potentials in pediatric population.  Zabok, Healtcare studies, Pediatrics.
  62. I. Mikula. Electrophysiologic diagnostics in spinal canal stenosis. Doctorate course of category one. Zagreb, 2015.
  63. I. Mikula. Needle and superficial electromyoneurography – what is the difference? Lecture for family medicine doctors of the Kparinsko-Zagorska County. 2015.
  64. I Mikula, M Bošnjak Pašić. Nerve lesions in Knee Dislocations., World Congress of Neurology, Rio de Janeiro, 2015

    2014.
  65. D. Primorac. The molecular basis of neuropathic pain. 7th World Congress, World Institute of Pain. Maastricht, The Netherlands, May 7-10, 2014.
  66. D. Primorac. Tailored genetics medicine. World Medicine Park. Minorca, May 7-11, 2014.
  67. D. Primorac. Genetics of neuropathic pain. 3rd Croatian Congress on Pain Therapy. Osijek, Croatia, May 22-24, 2014.
  68. D. Primorac. Toward excellence in pan management (roundtable). IMPACT proactive 2014, Florence, Italy, June 27-28, 2014
  69. D. Primorac. Education, Science and Technology Policies, based on the experience in Croatia. University of Botswana, Gaborone, October 14, 2014

    2013.
  70. D. Primorac. Communication to success. Croatian Nurses Association. Marija Bistrica, Croatia, April 12-14, 2013.
  71. D. Primorac. Private versus Public Healthcare. 1st International Congress: Person in Medicine and Health Care - Science and Art. Dubrovnik, April 18-21, 2013.
  72. D. Primorac. Molecular Genetics: The Present and the Future. The 2nd International Symposium “Vera Johanides”-Biotechnology in Croatia by 2020. Croatian Academy of Technical Sciences. Zagreb, Croatia, May 10-11 2013.
  73. D. Primorac.Current concepts of Osteogenesis Imperfecta. The 34th Anthropology and Health Conference. Anthropology and personalized medicine: impacting the future of comprehensive healthcare. Dubrovnik, Croatia, September 9-13, 2013.
  74. D. Primorac. Advances in Osteogenesis Imperfecta: Pathways to personalized medicine. 1st International Congress of the International College of Person-centered Medicine. Zagreb, Croatia, November 7-10, 2013.
Eu Logo
ESIF Logo
Hamag-Bicro Logo
Privacy policy | Cookie Declaration
Menu
Select Language
Call us
0800 84 88